CLINICAL_TRIALS
trial_result
· 2022-08-16
Clinical Trial Update: A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients [Phase 2]
Summary
Phase 2 trial update on PK, safety, and tolerability of peripheral and central infusion of melflufen in relapsed/refractory multiple myeloma (RRMM).
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Oncopeptides AB | Conditions: RRMM | Phase 2 | Status: TERMINATED | Results posted: 2022-08-16